Business Context and Reporting Period
This Form 8-K Current Report from vTv Therapeutics Inc. covers events occurring on May 31, 2018, and June 1, 2018. The company is a Delaware corporation focused on developing phosphodiesterase type 4 inhibitors, including the compound HPP737.
Key Financial Metrics and Agreements
- License Agreement: Entered into a definitive agreement with Newsoara Biopharma Co., Ltd. on May 31, 2018.
- Upfront Payment: Received an initial license fee of $2.0 million.
- Potential Milestones: Eligible for up to $63.0 million in additional development, regulatory, and sales-based milestone payments.
- Royalties: Entitled to mid-single to low-double digit royalty rates on annual net sales in the licensed territory (Mainland China, Hong Kong, Macau, Taiwan, and other Pacific Rim countries).
- Financial Statements: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Listing Status
On June 1, 2018, the company received notification from NASDAQ regarding non-compliance with Listing Rule 5450(b)(2)(C). The market value of the company's publicly held shares (MVPHS) fell below $15 million for 30 consecutive business days. This notification does not immediately affect the listing status of the Class A common stock.
Outlook, Risks, and Contingencies
- Compliance Period: The company has 180 calendar days (until November 28, 2018) to regain compliance with NASDAQ listing standards.
- Compliance Path: Compliance can be achieved if the MVPHS reaches or exceeds $15 million for 10 consecutive business days within the 180-day window.
- Risk of Delisting: Failure to regain compliance may result in the removal of the Class A Common Stock from The NASDAQ Global Market, subject to an appeals process.
- Management Action: Management intends to actively monitor the MVPHS and is evaluating options to regain compliance.
- Agreement Termination: The Newsoara License Agreement allows Newsoara to terminate at will upon prior written notice, and either party may terminate for uncured material breach or insolvency.
Investor Verification Checklist
- Verify the receipt and accounting treatment of the $2.0 million upfront license fee in the upcoming Form 10-Q.
- Monitor the daily market value of publicly held shares to assess progress toward the $15 million threshold required for NASDAQ compliance.
- Review the full text of the Newsoara License Agreement (to be filed as an exhibit to the June 30, 2018 Form 10-Q) for specific milestone definitions and termination clauses.
- Track any public announcements regarding the company's strategy to regain NASDAQ listing compliance before the November 28, 2018 deadline.